Zentalis Pharmaceuticals, Inc. — Investor Relations & Filings

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company's approach targets fundamental biological pathways to develop differentiated therapies. Its lead product candidate is azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor. Azenosertib is being evaluated in multiple clinical trials, both as a monotherapy and in combination with other agents, for various solid tumors, including uterine serous carcinoma and ovarian cancer. Several of its clinical programs for azenosertib have received Fast Track Designation from the U.S. Food and Drug Administration.